Mga Batayang Estadistika
| CIK | 855683 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Milestone Scientific Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific In |
|
| August 5, 2025 |
Exhibit 99.1 Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer Seasoned executive with proven track record driving growth and building customer focused teams to lead Milestone’s next phase of commercial execution Roseland, NJ, August 1, 2025 – Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Number |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific I |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numb |
|
| April 22, 2025 |
Letter from Marcum LLP, dated April 22, 2025, addressed to the Securities and Exchange Commission. Exhibit 16.1 April 22, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Milestone Scientific, Inc. under Item 4.01 of its Form 8-K dated April 22, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Milestone Scientific, Inc. |
|
| April 15, 2025 |
Certificate of Incorporation of Milestone as restated and amended as of March 25, 2025. * Exhibit 3.1 |
|
| April 15, 2025 |
Form of Promissory Note, dated April 8,2025* Exhibit 4.6 THIS NOTE AND THE SECURITIES ISSUABLE UPON PAYMENT OR CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| April 15, 2025 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Innovations Inc. Delaware |
|
| March 28, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2025 MILESTONE SCIENTIFIC INC. |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2024 MILESTONE SCIENTIFIC INC. |
|
| December 20, 2024 |
Exhibit 10.1 |
|
| November 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact |
|
| November 14, 2024 |
Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO Exhibit 99.1 Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO Roseland, NJ, November 14, 2024 – Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 MILESTONE SCIENTIFIC INC. |
|
| September 27, 2024 |
The Company’s investor presentation materials (Furnished) Exhibit 99.1 |
|
| September 27, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2024 MILESTONE SCIENTIFIC INC. |
|
| August 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name |
|
| July 18, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| June 5, 2024 |
MILESTONE SCIENTIFIC AND SUBSIDIARIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific I |
|
| April 9, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| March 29, 2024 |
Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT RECITALS WHEREAS, an employment agreement (the “Agreement”) was entered into as of January 1, 2022 by and between Arjan Haverhals (the “Executive”) and Milestone Scientific Inc. (the “Company” and together with the Executive, the “Parties”); and WHEREAS, the Parties have agreed to amend the Agreement (this “Amendment”). NOW, THEREFORE, in considerati |
|
| March 29, 2024 |
Exhibit 19.1 Insider Trading Policy Under United States securities laws, it is a crime to buy or sell securities of a company (including stocks or bonds) while in possession of material, non-public information about the company. Furthermore, it is a crime to pass on such information to others who use it for personal profit if the information was obtained in the course of one’s employment and discl |
|
| March 29, 2024 |
Exhibit 99.1 MILESTONE SCIENTIFIC INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION A. OVERVIEW In accordance with the applicable rules of The New York Stock Exchange (the “NYSE Rules”), and Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Milestone Scientific Inc. (the “Company |
|
| March 29, 2024 |
Exhibit 14.1 MILESTONE SCIENTIFIC INC. CODE OF BUSINESS CONDUCT AND ETHICS This Code of Ethics applies to the Board of Directors, officers and employees of Milestone Scientific Inc. (the “Company”) and its subsidiaries (collectively, "Milestone Personnel") and is intended to qualify as a "code of ethics" within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules promulgated |
|
| March 29, 2024 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Innovations Inc. Delaware |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| December 12, 2023 |
MILESTONE SCIENTIFIC INC. 4,765,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275088 MILESTONE SCIENTIFIC INC. 4,765,000 Shares of Common Stock We are offering 4,765,000 shares of our common stock, par value $0.001 per share (“common stock”) pursuant to this prospectus supplement and the accompanying base prospectus in a firm commitment public offering. The purchase price for each share of common stock is $0.63. Our comm |
|
| December 12, 2023 |
Underwriting Agreement, dated as of December 10, 2023, between the Company and Maxim Group LLC (11) Exhibit 1.1 (Underwriting Agreement) 4,765,000SHARES OF COMMON STOCK MILESTONE SCIENTIFIC INC. UNDERWRITING AGREEMENT December 10, 2023 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned, Milestone Scientific Inc., a company incorporated under |
|
| December 12, 2023 |
Milestone Scientific Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 (Launch Press Release) Milestone Scientific Inc. Announces Proposed Public Offering of Common Stock ROSELAND, N.J., Dec. 8, 2023 (GLOBE NEWSWIRE) - Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its commo |
|
| December 12, 2023 |
Milestone Scientific Inc. Announces Pricing of $3.0 Million Public Offering of Common Stock Exhibit 99.2 (Pricing Press Release) Milestone Scientific Inc. Announces Pricing of $3.0 Million Public Offering of Common Stock ROSELAND, N.J., Dec. 10, 2023 (GLOBE NEWSWIRE) - Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the pricing of an underwritten public offering of 4,765,000 |
|
| December 8, 2023 |
Subject to completion, dated December 8, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-275088 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, nor are they soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to com |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientif |
|
| October 26, 2023 |
Milestone Scientific Inc. 425 Eagle Rock Ave, Suite 403 Roseland, New Jersey 07068 Milestone Scientific Inc. 425 Eagle Rock Ave, Suite 403 Roseland, New Jersey 07068 October 26, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Ben Richie, Esq Re: Milestone Scientific Inc. Registration Statement on Form S-3, File No. 333- 275088 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: October 30 |
|
| October 19, 2023 |
Calculation of Registration Statement Fee** Exhibit 107.1 CALCULATION OF REGISTRATION FEE Form S-1 Milestone Scientific Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid E |
|
| October 19, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Num |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific In |
|
| July 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Milestone Scientific Inc. |
|
| July 13, 2023 |
As filed with the Securities and Exchange Commission on July 13, 2023 As filed with the Securities and Exchange Commission on July 13, 2023 Registration No. |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Number |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific I |
|
| May 10, 2023 |
Section 1350 Certifications-Chief Executive Officer** Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of Milestone Scientific Inc. (“Milestone”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Arjan Haverhals Chief Executive Officer of M |
|
| May 10, 2023 |
Section 1350 Certifications-Chief Financial Officer** Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of Milestone Scientific Inc. (“Milestone”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Arjan Haverhals Chief Executive Officer of M |
|
| May 10, 2023 |
Rule 13a-14(a) Certification-Chief Executive Officer* Exhibit 31.1 Rule 13a-14(a)/15d-14(a) Certification I, Arjan Haverhals, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were m |
|
| May 10, 2023 |
Rule 13a-14(a) Certification-Chief Financial Officer* Exhibit 31.2 Rule 13a-14(a)/15d-14(a) Certification I, Peter Milligan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were ma |
|
| May 1, 2023 |
MILESTONE SCIENTIFIC AND SUBSIDIARIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| March 30, 2023 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Medical Inc. Delaware |
|
| March 30, 2023 |
Offer Letter, dated as of February 1, 2023, between Peter Milligan and Milestone Scientific Inc.* ** Exhibit 10.25 As of February 1, 2023 Peter J. Milligan 13 Crest Drive Randolph, New Jersey 07869 Dear Peter, This letter confirms our previous conversations regarding the employment opportunity available to you with Milestone Scientific Inc. (the "Company") and sets forth the terms and conditions of that employment, effective February 1, 2023 (the "Commencement Date"). 1. Position; Duties: The Com |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Num |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientif |
|
| October 18, 2022 |
Letter from Friedman LLP dated as of October 18, 2022 Exhibit 16.1 October 18, 2022 Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, D.C. 20549 Re: Milestone Scientific, Inc. Commission File Number 001-14053 Dear Sir or Madam: We have read the statements made by Milestone Scientific, Inc. under Item 4.01 of its Form 8-K dated October 18, 2022. We agree with the statements concerning our firm in such Form |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| August 15, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this ?Agreement?) dated as of January 1 2022 between ARJAN HAVERHALS (the ?Executive?) and MILESTONE SCIENTIFIC INC. (the ?Company?). WHEREAS, the Executive is currently the President and Chief Executive Officer of the Company; and WHEREAS, the parties desire, by this Agreement, to set forth the terms and conditions of the employment relation |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific In |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific I |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numb |
|
| April 29, 2022 |
MILESTONE SCIENTIFIC AND SUBSIDIARIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| March 31, 2022 |
Exhibit 10.21 BUY AND SELL AGREEMENT THIS AGREEMENT (the ?Agreement?), is entered into as of November 22, 2021, (the ?Effective Date?) by and between WAND DENTAL, INC., (?Wand Dental?), a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 425 Eagle Rock Avenue, Roseland, NJ 07068, USA and Michelle Zhang dba Solee Science & Techn |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scie |
|
| March 31, 2022 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Medical Inc. Delaware |
|
| March 31, 2022 |
Description of Registrant’s Securities* EXHIBIT 4.6 DESCRIPTION OF REGISTRANT'S SECURITIES Common Stock Our authorized capital stock includes 100,000,000 shares of common stock, par value $0.001 per share. As of March 31, 2022 there were of 68,120,003 shares of common stock issued and outstanding, and 33,333 shares of common stock held in the treasury. The following description of the rights of the common stock do not apply to the treas |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2022 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commiss |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientif |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific In |
|
| July 14, 2021 |
As filed with the Securities and Exchange Commission on July 14, 2021 As filed with the Securities and Exchange Commission on July 14, 2021 Registration No. |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Number |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific I |
|
| April 30, 2021 |
Amended and Restated 2020 Equity Incentive Plan (28) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ?Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| April 7, 2021 |
Succession Agreement between Leonard Osser and Milestone Scientific Inc. (27) Exhibit 10.1 425 Eagle Rock Ave, Suite 403 Roseland, NJ 07068 April 6, 2021 Leonard Osser Camlet Court Roseland, New Jersey 07068 Re: Succession Agreement Dear Leonard, As part of the Succession Plan of Milestone Scientific Inc., a Delaware corporation (the ?Company?), you have agreed with the Company to restructure certain of your existing agreements with the Company and to provide for additional |
|
| March 31, 2021 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Medical Inc. Delaware Milestone Advanced Cosmetic Systems Inc. Delaware Milestone Education LLC (inactive February 28,2019) Nevada |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scie |
|
| March 31, 2021 |
Description of Registrant’s Securities* Exhibit 4.6 DESCRIPTION OF REGISTRANT'S SECURITIES Common Stock Our authorized capital stock includes 85,000,000 shares of common stock, par value $0.001 per share. As of March 29, 2020, there were 65,647,157 shares of common stock issued and outstanding, and 33,333 shares of common stock held in the treasury. The following description of the rights of the common stock do not apply to the treasury |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numb |
|
| March 3, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| February 1, 2021 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 OMB Number: 3235-0101 Expires: December 31, 2009 Estimated average burden hours per response…….….2.00 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. ATTENTION: Transmit for filing 3 copies of this form concurrently with either |
|
| January 14, 2021 |
As filed with the Securities and Exchange Commission on January 14, 2021 Registration No. |
|
| December 11, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| November 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientif |
|
| October 26, 2020 |
Milestone Scientific Inc. 2020 Equity Incentive Plan1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| October 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 1, 2020 |
Milestone Scientific Promotes Arjan Haverhals to President of Milestone Scientific Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Milestone Scientific Promotes Arjan Haverhals to President of Milestone Scientific ROSELAND, NJ, September 1, 2020 – Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, toda |
|
| September 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Num |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific In |
|
| June 26, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231178 Prospectus Supplement (To the Prospectus dated May 16, 2019) MILESTONE SCIENTIFIC INC. 6,520,000 Shares of Common Stock Warrants to Purchase 3,260,000 Shares of Common Stock We are offering 6,520,000 shares of our common stock, par value $0.001 per share (“common stock”) and warrants to purchase 3,260,000 shares of our common stock (and |
|
| June 26, 2020 |
Underwriting Agreement, dated as of June 25, 2020 between the Company and Maxim Group LLC (26) Exhibit 1.1 6,520,000 Shares of Common Stock and Warrants to Purchase 3,260,000 Shares of Common Stock MILESTONE SCIENTIFIC INC. UNDERWRITING AGREEMENT June 25, 2020 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Ladies and Gentlemen: Milestone Scientific Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to se |
|
| June 26, 2020 |
Form of Common Stock Purchase Warrant issued in the Jun. 2020 Public Offering (26) Exhibit 4.1 COMMON STOCK PURCHASE WARRANT MILESTONE SCIENTIFIC INC. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”, and the term “Warrants” below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company (as defined below) on the date hereof) certifies that, for value received, or its assigns (the “Holder”) is |
|
| June 26, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| June 26, 2020 |
Milestone Scientific Announces Pricing of $14.0 Million Offering of Common Stock and Warrants Exhibit 99.1 Milestone Scientific Announces Pricing of $14.0 Million Offering of Common Stock and Warrants ROSELAND, N.J., June 25, 2020 - Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced today the pricing of an underwritten offering of 6,520,000 shares of its common stock and warr |
|
| June 25, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231178 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, nor are they soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to com |
|
| June 10, 2020 |
Milestone Scientific Inc. Office: (973) 535-2717 Fax: (973) 535-2829 425 Eagle Rock Ave., Ste. 403 Roseland, New Jersey 07068 June 10, 2020 United States SECURITY AND EXCHANGE COMMISSION Division of Corporate Finance Office of Life Science Washington, D.C. 20549 RE: Milestone Scientific Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 30, 2020 File No. 001 – 14053 Dear Mr. Er |
|
| May 22, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Number |
|
| May 22, 2020 |
Milestone Scientific Regains Compliance with New York Stock Exchange Listing Standards Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Milestone Scientific Regains Compliance with New York Stock Exchange Listing Standards LIVINGSTON, NJ, May 22, 2020 - Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, tod |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientifi |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numb |
|
| April 9, 2020 |
Form of Common Stock Purchase Warrant issued in the Apr. 2020 Public offering (25) Exhibit 4.1 COMMON STOCK PURCHASE WARRANT MILESTONE SCIENTIFIC INC. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”, and the term “Warrants” below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company (as defined below) on the date hereof) certifies that, for value received, or its assigns (the “Holder”) is |
|
| April 9, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231178 Prospectus Supplement (To the Prospectus dated May 16, 2019) MILESTONE SCIENTIFIC INC. 4,750,000 Shares of Common Stock Warrants to Purchase 2,375,000 Shares of Common Stock We are offering 4,750,000 shares of our common stock, par value $0.001 per share (“common stock”) and warrants to purchase up to 2,375,000 shares of our common stock |
|
| April 9, 2020 |
Exhibit 99.1 Milestone Scientific Announces Pricing of Above Market $4.5 Million Offering of Common Stock and Warrants ROSELAND, N.J., Apr. 9, 2020 - Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced today the pricing of an underwritten offering of 4,750,000 shares of its common stoc |
|
| April 9, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| April 9, 2020 |
Underwriting Agreement, dated as of April 9, 2020 between the Company and Maxim Group LLC (25) Exhibit 1.1 4,750,000 Shares of Common Stock and Warrants to Purchase 2,375,000 Shares of Common Stock MILESTONE SCIENTIFIC INC. UNDERWRITING AGREEMENT April 9, 2020 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Ladies and Gentlemen: Milestone Scientific Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to se |
|
| April 8, 2020 |
Subject to completion, dated April 8, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-231178 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, nor are they soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to com |
|
| April 2, 2020 |
Annual Report on Form 10-K/A for the fiscal year ended December 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-140 |
|
| April 2, 2020 |
Certificate of Amendment to Restated Certificate of Incorporation (24) Exhibit 3.4 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF MILESTONE SCIENTIFIC INC. The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Milestone Scientific Inc. resolutions were duly adopted setting forth a proposed amendment of the Resta |
|
| April 2, 2020 |
Exhibit 4.6 Description of registrant's securities Common Stock Our authorized capital stock includes 75,000,000 shares of common stock, par value $0.001 per share. As of March 31, 2020, there were 49,893,534 shares of common stock issued and outstanding, and 33,333 shares of common stock held in the treasury. The following description of the rights of the common stock do not apply to the treasury |
|
| March 30, 2020 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Medical Inc. Delaware Milestone Advanced Cosmetic Systems Inc. Delaware Milestone Education LLC (inactive February 28,2019) Nevada |
|
| March 30, 2020 |
Annual Report on Form 10-K for the fiscal year ended December 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| February 20, 2020 |
MLSS / Milestone Scientific Inc. / Ginsberg Debra Lynn Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Milestone Scientific Inc. (Name of Issuer) Common Stock, $0.001 Par Value per Share (Title of Class of Securities) 59935P100 (CUSIP Number) May 21, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 19, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| November 14, 2019 |
MLSS / Milestone Scientific Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| November 5, 2019 |
MLSS / Milestone Scientific Inc. DEF 14A - - FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| October 4, 2019 |
MLSS / Milestone Scientific Inc. PRE 14A - - FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2019 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| August 14, 2019 |
MLSS / Milestone Scientific Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific |
|
| May 20, 2019 |
$30,000,000 MILESTONE SCIENTIFIC INC. Common Stock Preferred Stock Debt Securities Filed Pursuant to Rule 424(b)(2) Registration No. 333-231178 PROSPECTUS $30,000,000 MILESTONE SCIENTIFIC INC. Common Stock Preferred Stock Debt Securities Warrants Units This prospectus relates to common stock, preferred stock, debt securities, warrants and units that we may sell from time to time in one or more offerings up to a total public offering price of $30,000,000 on terms to be determined |
|
| May 14, 2019 |
MLSS / Milestone Scientific Inc. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific |
|
| May 13, 2019 |
MLSS / Milestone Scientific Inc. CORRESP - - Milestone Scientific Inc. 220 South Orange Avenue Livingston, NJ 07039 May 13, 2019 Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Milestone Scientific Inc. Registration Statement on Form S-3 File No. 333-231178 Ladies and Gentlemen: In connection with the above referenced Registration Statement on Form S-3 of Milestone Scientific Inc., the undersigned, a duly el |
|
| May 2, 2019 |
MLSS / Milestone Scientific Inc. S-3 FORM S-3 As filed with the Securities and Exchange Commission on May 2, 2019 Registration No. |
|
| May 2, 2019 |
Exhibit 4.1 FORM OF INDENTURE MILESTONE SCIENTIFIC INC. as Issuer as Trustee Dated as of , 20 DEBT SECURITIES TABLE OF CONTENTS ARTICLE I Definitions and Incorporation by Reference SECTION 1.01. Definitions. 1 SECTION 1.02. Other Definitions. 4 SECTION 1.03. Incorporation by Reference of Trust Indenture Act 4 SECTION 1.04. Rules of Construction 5 SECTION 1.05. Acts of Holders 5 ARTICLE II The Secu |
|
| April 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2019 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Numbe |
|
| April 1, 2019 |
Amended and Restated By-laws of Milestone filed April 1, 2019 (23) Exhibit 3.4 AMENDED and RESTATED BYLAWS OF MILESTONE SCIENTIFIC INC (A Delaware Corporation) ARTICLE I OFFICES Section 1. Principal Office. The principal business office of Milestone Scientific Inc. (the “Corporation”) shall be at such location as the Board of Directors of the Corporation (the “Board”) shall, from time to time designate. Section 2. Other Offices. The Corporation may also have offi |
|
| April 1, 2019 |
MLSS / Milestone Scientific Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| April 1, 2019 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Medical Inc. Delaware Milestone Advanced Cosmetic Systems Inc. Delaware Milestone Education LLC Nevada |
|
| February 14, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Milestone Scientific Inc. 220 South Orange Avenue Livingston, New Jersey 07039 Ladies & Gentlemen: Whereas, on February 1, 2019, Milestone Scientific Inc., a Delaware corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Maxim Group LLC, acting as sole underwriter and book-running manager, for a public offe |
|
| February 14, 2019 |
Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Milestone Scientific Announces Private Placement by Entity Affiliated with Board Member & CEO of the Company’s Wand Dental Subsidiary LIVINGSTON, NJ, February 14, 2019 – Milestone Scientific Inc. (NYSE: MLSS) today announced that BP4 S.p.A. (“BP4”), a principal stockho |
|
| February 14, 2019 |
Form of Common Stock Purchase Warrant issued in the Feb. 2019 Private Placement (22) Exhibit 4.1 COMMON STOCK PURCHASE WARRANT MILESTONE SCIENTIFIC INC. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”, and the term “Warrants” below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company (as defined below) on the date hereof) certifies that, for value received, or its assigns (the “Holder”) is |
|
| February 14, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2019 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| February 1, 2019 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-209466 Prospectus Supplement (To the Prospectus dated May 4, 2016) MILESTONE SCIENTIFIC INC. 5,715,000 Shares of Common Stock Warrants to Purchase 1,428,750 Shares of Common Stock We are offering 5,715,000 shares of our common stock, par value $0.001 per share (“common stock”) and warrants to purchase 1,428,750 shares of our common stock (and t |
|
| February 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2019 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Nu |
|
| February 1, 2019 |
Exhibit 99.1 Milestone Scientific Announces Pricing of $2.0 Million Offering of Common Stock and Warrants LIVINGSTON, N.J., Feb. 1, 2019 - Milestone Scientific Inc. (MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced today the pricing of an underwritten offering of 5,715,000 shares of its common stock and warrants to purchas |
|
| February 1, 2019 |
Exhibit 1.1 5,715,000 Shares of Common Stock and 1,428,750 Warrants to Purchase Shares of Common Stock MILESTONE SCIENTIFIC INC. UNDERWRITING AGREEMENT February 1, 2019 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Ladies and Gentlemen: Milestone Scientific Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to |
|
| February 1, 2019 |
Form of Common Stock Purchase Warrant issued in the Feb. 2019 Public Offering (21) Exhibit 4.1 COMMON STOCK PURCHASE WARRANT MILESTONE SCIENTIFIC INC. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”, and the term “Warrants” below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company (as defined below) on the date hereof) certifies that, for value received, or its assigns (the “Holder”) is |
|
| January 31, 2019 |
SUBJECT TO COMPLETION, DATED January 31, 2019 Filed Pursuant to Rule 424(b)(5) Registration No. 333-209466 The information in this preliminary prospectus supplement is not complete and may be changed. The preliminary prospectus supplement is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED January 31, 2019 Prospe |
|
| January 25, 2019 |
Press Release, dated January 25, 2019 Exhibit 10.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 New York Stock Exchange Accepts Milestone Scientific’s Plan to Regain Compliance LIVINGSTON, NJ, January 25, 2019 - Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today |
|
| January 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2018 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File |
|
| November 23, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2018 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File N |
|
| November 16, 2018 |
MLSS / Milestone Scientific Inc. FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14 |
|
| November 14, 2018 |
MLSS / Milestone Scientific Inc. FORM 10-Q (Quarterly Report) FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Miles |
|
| August 14, 2018 |
MLSS / Milestone Scientific Inc. FORM 10-Q (Quarterly Report) FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone |
|
| June 1, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2018 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Number |
|
| May 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2018 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific |
|
| April 30, 2018 |
MLSS / Milestone Scientific Inc. FORM DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 30, 2018 |
MLSS / Milestone Scientific Inc. FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 2, 2018 |
MLSS / Milestone Scientific Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| March 20, 2018 |
MLSS / Milestone Scientific Inc. / Ginsberg Debra Lynn Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Milestone Scientific Inc. (Name of Issuer) Common Stock, $0.001 Par Value per Share (Title of Class of Securities) 59935P100 (CUSIP Number) March 19, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 19, 2017 |
Leonard Osser to Re-Assume Role as CEO of Milestone Scientific EX-99.1 2 ex102285.htm EXHIBIT 99.1 Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Leonard Osser to Re-Assume Role as CEO of Milestone Scientific LIVINGSTON, NJ, December 18, 2017 - Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precis |
|
| December 19, 2017 |
mlss201712198k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2017 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 |
|
| November 14, 2017 |
MLSS / Milestone Scientific Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ● QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ● TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILES |
|
| October 6, 2017 |
mlss201710068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2017 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 ( |
|
| October 5, 2017 |
mlss201710058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2017 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-14053 ( |
|
| October 5, 2017 |
Milestone Scientific Announces Appointment of Leslie Bernhard as Interim CEO ex96345.htm Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Milestone Scientific Announces Appointment of Leslie Bernhard as Interim CEO LIVINGSTON, NJ, October 5, 2017 - Milestone Scientific Inc. (NYSE: MLSS), a developer of painless and precise computerized drug delivery instruments, today announced the appointmen |
|
| September 6, 2017 |
ex99-1.htm Exhibit 99.1 |
|
| September 6, 2017 |
Financial Statements and Exhibits, Other Events mlss201708308k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 6, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of inco |
|
| August 14, 2017 |
Exhibit 10.8 CONSULTING AGREEMENT CONSULTING AGREEMENT (the “Agreement”) dated as of July 10, 2017 between Milestone Medical Inc., a Delaware corporation (the “Company”) and U.S. Asian Consulting Group, LLC, a Delaware limited liability company (the “Consultant”). WHEREAS, Leonard Osser (“Osser”) is the sole member of Consultant; and WHEREAS, Osser is currently the Chief Executive Officer of the C |
|
| August 14, 2017 |
MLSS / Milestone Scientific Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
|
| July 17, 2017 |
Financial Statements and Exhibits mlss201707138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpor |
|
| July 11, 2017 |
ex99-1.htm Exhibit 99.1 Following Successful FDA Marketing Clearance of the CompuFlo™ Epidural Instrument, Milestone Scientific Appoints Daniel Goldberger as CEO to Lead Transition to a Commercially Focused Global Medical Device Company Leonard Osser to Continue as Director of China Operations and a Board Member LIVINGSTON, NJ, July 11, 2017 - Milestone Scientific Inc. (NYSE: MLSS), developer of p |
|
| July 11, 2017 |
ex4.htm Exhibit 10.3 Covenant Agreement This Covenant Agreement (the ?Agreement?), dated and effective as of July 10, 2017, is made by and between Milestone Scientific Inc., a Delaware corporation (together with its successors and affiliates, the ?Company?) and Daniel Goldberger (the ?Executive?). This Agreement is entered into pursuant to the Employment Agreement dated July 10, 2017 between the C |
|
| July 11, 2017 |
ex1.htm Exhibit 10.1 EXECUTION COUNTERPART EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 10, 2017 between LEONARD OSSER (the “Executive”) and MILESTONE SCIENTIFIC INC. (the “Company”). WHEREAS, the Executive is currently the Chief Executive Officer of the Company; and WHEREAS, the Board of Directors of the Company (the “Board”) desires to provide for a succession pl |
|
| July 11, 2017 |
ex10-2.htm Exhibit 10.2 Execution EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this ?Agreement?) dated as of July 10, 2017 between DANIEL S. GOLDBERGER (the ?Executive?) and MILESTONE SCIENTIFIC INC. (the ?Company?). WHEREAS, the Company desires to employ the Executive as its President and Chief Executive Officer; and WHEREAS, the Executive desires be employed as the President and Chief Executive Of |
|
| July 11, 2017 |
mlss201707088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 10, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 0-26284 13-3545623 (State or other jurisdiction of incorporat |
|
| June 12, 2017 |
Financial Statements and Exhibits, Other Events mlss201706128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpor |
|
| June 12, 2017 |
MILESTONE SCIENTIFIC ANNOUNCES 510(k) FDA CLEARANCE FOR COMPUFLO® EPIDURAL INSTRUMENT ex99-1.htm Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 MILESTONE SCIENTIFIC ANNOUNCES 510(k) FDA CLEARANCE FOR COMPUFLO? EPIDURAL INSTRUMENT LIVINGSTON, NJ, June 12, 2017 - Milestone Scientific Inc. (NYSE: MLSS) today announced that the CompuFlo? Epidural Computer Controlled Anesthesia System has received 510(k) |
|
| June 7, 2017 |
ex10-1.htm Exhibit 10.1 MEMORANDUM OF AGREEMENT This Stock Purchase Agreement (this “Agreement”) is made and entered into as of the 6th day of June, 2017, by and between Milestone Scientific Inc., a Delaware corporation (“Seller”), and Solee Science & Technology U.S.A., Ltd., a Delaware corporation (“Purchaser”; Seller and Purchaser, each a “Party” and, together, the “Parties” ). W I T N E S S E T |
|
| June 7, 2017 |
ex10-2.htm Exhibit 10.2 PROMISSORY NOTE U.S.$1,275,000 Berkeley Heights, New Jersey As of June 6, 2017 FOR VALUE RECEIVED, the undersigned, Solee Science & Technology, USA Ltd. (the "Company"), a Delaware corporation having its principal office at 100 Connell Drive #2300, Berkeley Heights, New Jersey 07922, hereby promises to pay to Milestone Scientific Inc. ("Seller"), a Delaware corporation havi |
|
| June 7, 2017 |
ex10-3.htm Exhibit 10.3 STOCK OPTION AGREEMENT STOCK OPTION AGREEMENT, dated as of June 6, 2017, between Solee Science & Technology, USA, Ltd., Inc., a Delaware corporation (the ?Grantor?), and Milestone Scientific Inc., a Delaware corporation (the ?Grantee?). WHEREAS, Grantor and Grantee are simultaneously with the execution and delivery of this Agreement entering into a Stock Purchase Agreement |
|
| June 7, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits mlss201706068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpora |
|
| June 2, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits mlss201706028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpora |
|
| June 2, 2017 |
ex10-1.htm Exhibit 10.1 Execution Version (2) Asset Purchase Agreement This Agreement is dated: June 2, 2017 PARTIES (1) APAD Octrooi B.V. incorporated and registered in The Netherlands and having its principal place of business at Henri Dunantstraat 1, 5223 GZ Den Bosch, The Netherlands (APAD O); (2) APAD B.V incorporated and registered in The Netherlands and having its principal place of busines |
|
| May 25, 2017 |
mlss201705258k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2017 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpora |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
|
| April 12, 2017 |
Milestone Scientific FORM DEF 14A mlss20170410def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ? |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| February 1, 2017 |
MLSS / Milestone Scientific Inc. / Ginsberg Debra Lynn Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Milestone Scientific Inc. (Name of Issuer) Common Stock, $0.001 Par Value per Share (Title of Class of Securities) 59935P100 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| December 16, 2016 |
Form of Common Stock Purchase Warrant issued in the 2016 Public Offering (16) Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT MILESTONE SCIENTIFIC INC. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?, and the term ?Warrants? below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company (as defined below) on the date hereof) certifies that, for value received, or its assigns (the ?Hold |
|
| December 16, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commiss |
|
| December 16, 2016 |
Exhibit 1.1 2,000,000 Shares of Common Stock and 1,500,000 Warrants MILESTONE SCIENTIFIC INC. UNDERWRITING AGREEMENT December 16, 2016 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Acting severally on behalf of itself and as representative of the several Underwriters named on Schedule I annexed hereto. Ladies and Gentlemen: Milestone Scientific Inc., a Delaware corporation (the ?Company? |
|
| December 16, 2016 |
Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 MILESTONE SCIENTIFIC INC. PRICES PUBLIC OFFERING OF COMMON STOCK AND WARRANTS FOR GROSS PROCEEDS OF $3 MILLION LIVINGSTON, NJ, December 16, 2016 - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D and dental products company that designs, patents, incubates and |
|
| December 16, 2016 |
mlss20161208424b2.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-209466 PROSPECTUS SUPPLEMENT (To the Prospectus dated May 4, 2016) MILESTONE SCIENTIFIC INC. 2,000,000 Shares of Common Stock Warrants to Purchase 1,500,000 Shares of Common Stock We are offering 2,000,000 shares of our common stock, par value $0.001 per share (?common stock?) and warrants to purchase 1,500,000 shares of o |
|
| December 15, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commiss |
|
| December 15, 2016 |
MILESTONE SCIENTIFIC INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 MILESTONE SCIENTIFIC INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS LIVINGSTON, NJ, December 15, 2016 - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D and dental products company that designs, patents, incubates and commercializes a gro |
|
| December 15, 2016 |
mlss20161208424b2.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-209466 The information in this preliminary prospectus supplement is not complete and may be changed. The preliminary prospectus supplement is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. PRELIMINARY PROSPECTUS SUPPLEM |
|
| December 2, 2016 |
Milestone Scientific FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 1, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commissi |
|
| December 2, 2016 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) dated as of December 1, 2016 between GIAN DOMENICO TROMBETTA (the ?Executive?) and WAND DENTAL INC. (the ?Company?). WHEREAS, the Company and the Executive are parties to an Employment Agreement dated as of September 1, 2014 pursuant to which the Executive serves as the Chief Executi |
|
| November 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILES |
|
| August 26, 2016 |
mlss201608248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 0-26284 13-3545623 (State or other jurisdiction of incorpor |
|
| August 26, 2016 |
mlss201608248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 0-26284 13-3545623 (State or other jurisdiction of incorpor |
|
| August 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
|
| July 22, 2016 |
MILESTONE SCIENTIFIC INC. Common Stock mlss20160722424b2.htm Filed Pursuant to Rule 424(b)(2) Registration No. 333-209466 $250,080 MILESTONE SCIENTIFIC INC. Common Stock We are offering 104,200 shares of common stock, par value $0.001 per share pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the NYSE MKT under the symbol ?MLSS?. The last reported sale price of our shares of common s |
|
| July 21, 2016 |
Baker Tilly Virchow Krause, LLP ex16-1.htm Exhibit 16.1 Baker Tilly Virchow Krause, LLP One Penn Plaza, Suite 3000 New York, NY 10119 tel 212 697 6900 fax 212 490 1412 bakertilly.com July 21, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Milestone Scientific Inc. (CIK 0000855683) Commissioners: We have read the statements made by Milestone Scientific Inc. pursuant to item 4.01 of Form 8-K, w |
|
| July 21, 2016 |
Milestone Scientific FORM 8-K (Current Report/Significant Event) mlss201607208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpor |
|
| July 13, 2016 |
MLSS / Milestone Scientific Inc. / Gintel Robert M Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Milestone Scientific Inc. (Name of Issuer) Common Stock, $0.001 Par Value per Share (Title of Class of Securities) 59935P100 (CUSIP Number) July 12, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 30, 2016 |
EX-99.D Exhibit D Milestone Scientific Inc. 220 South Orange Avenue Livingston, New Jersey 07039 Tel: (973) 535-2717 Fax: (973) 535-2829 June 15, 2016 Via e-mail and Regular Mail [email protected] BP4 S.p.A c/o Innovest S.p.A. Corso Venezia 44 Milan, Italy Re: Milestone Scientific Inc. (“Milestone”) Dear Sirs: This will confirm that Milestone has agreed to sell to you and you hav |
|
| June 30, 2016 |
ex10-1.htm Exhibit 10.1 EXCLUSIVE DISTRIBUTION AND SUPPLY AGREEMENT This Exclusive Distribution and Supply Agreement (this ?Agreement?) is entered into as of June 20, 2016 by and among Milestone Scientific, Inc. (?Milestone?, but solely for the purposes of Section 1.1(b) and Section 13.2), Wand Dental, Inc. (?Supplier?) and Henry Schein, Inc. (?HSI?). 1. Appointment and Term. 1.1 (a) Subject to th |
|
| June 30, 2016 |
MLSS / Milestone Scientific Inc. / Bp4 S.r.l. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-102) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* MILESTONE SCIENTIFIC INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 59935P100 (CUSIP Number) Innovest S.p.A. Corso |
|
| June 30, 2016 |
ex99-1.htm Exhibit 99.1 Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Milestone Scientific, Inc. Announces Exclusive Distribution Agreement with Henry Schein, Inc. Distribution Agreement Includes Dedicated Specialty Sales Force and Guaranteed Minimums LIVINGSTON, NJ, June , 2016 - Milestone Scientific Inc. (NYSE MKT: MLSS), a |
|
| June 30, 2016 |
Milestone Scientific FORM 8-K (Current Report/Significant Event) mlss201606298k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpor |
|
| June 1, 2016 |
Milestone Scientific FORM 8-K (Current Report/Significant Event) mlss201605318k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorpora |
|
| May 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
|
| May 4, 2016 |
$30,000,000 MILESTONE SCIENTIFIC INC. Common Stock Preferred Stock Debt Securities 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-209466 $30,000,000 MILESTONE SCIENTIFIC INC. Common Stock Preferred Stock Debt Securities Warrants Units This prospectus relates to common stock, preferred stock, debt securities, warrants and units that we may sell from time to time in one or more offerings up to a total public offering price of $30,000,000 on terms to |
|
| May 2, 2016 |
CORRESP Milestone Scientific Inc. 220 South Orange Avenue Livingston, New Jersey 07039 (973) 535-2717 May 2, 2016 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Mr. Tim Buchmiller Re: Milestone Scientific Inc. (the ?Company?) Registration Statement on Form S-3 (the ?Registration Statement?) File No. 333-20946 |
|
| April 26, 2016 |
Milestone Scientific AMENDMENT NO. 1 TO FORM S-3 Amendment No. 1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on April 26, 2016 Registration No. 333-209466 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 3842 13-3 |
|
| April 26, 2016 |
EX-4.5 Exhibit 4.5 FORM OF INDENTURE MILESTONE SCIENTIFIC INC. as Issuer as Trustee Dated as of , 20 DEBT SECURITIES TABLE OF CONTENTS ARTICLE I Definitions and Incorporation by Reference SECTION 1.01. Definitions. 1 SECTION 1.02. Other Definitions. 4 SECTION 1.03. Incorporation by Reference of Trust Indenture Act 4 SECTION 1.04. Rules of Construction 5 SECTION 1.05. Acts of Holders 5 ARTICLE II T |
|
| April 26, 2016 |
MORSE, ZELNICK, ROSE & LANDER A LIMITED LIABILITY PARTNERSHIP 825 THIRD AVENUE NEW YORK, NEW YORK 10022 212-838-1177 FAX ? 212-208-6809 April 26, 2016 WRITER?S DIRECT LINE (212) 838-8599 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 25, 2016 |
Unregistered Sales of Equity Securities Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2016 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commission File |
|
| April 15, 2016 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| April 6, 2016 |
Certificate of Correction to the Certificate of Designation filed on May 12, 2014 (13) Exhibit 3.3 CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF MILESTONE SCIENTIFIC INC. Milestone Scientific Inc. (hereinafter called the "corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: 1. The name of the corporation is Milestone Scientific Inc. 2. |
|
| April 6, 2016 |
Exhibit 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware Milestone Medical Inc. Delaware |
|
| April 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| April 6, 2016 |
Agreement with Mark Hochman, dated July 2015 (13) Exhibit 10.11 July 31st, 2015 Dr. Mark Hochman 26 Meadow Woods Road Great Neck, New York 11020 Milestone Scientific Inc. 220 S. Orange Avenue Livingston, NJ 07039 CONSULTING AGREEMENT This agreement (this ?Consulting Agreement?) will confirm the agreement which we have reached with respect to your ongoing consulting services for Milestone Scientific Inc. (the ?Company?). 1. Engagement and Compensa |
|
| March 30, 2016 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 Commission File Number 001-14053 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 11-K ? Form 20-F ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| February 10, 2016 |
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on February 10, 2016 Registration No. |
|
| January 4, 2016 |
MLSS / Milestone Scientific Inc. / Gintel Robert M Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Milestone Scientific Inc. (Name of Issuer) Common Stock, $0.001 Par Value per Share (Title of Class of Securities) 59935P100 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILES |
|
| August 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 19, 2015 |
Milestone Scientific FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 17, 2015 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Co |
|
| May 28, 2015 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PUSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 220 South Or |
|
| May 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
|
| April 30, 2015 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| April 1, 2015 |
Milestone Scientific NOTIFICATION OF LATE FILING Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 Commission File Number 001-14053 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2014 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scien |
|
| April 1, 2015 |
EXHIBIT 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Wand Dental , Inc. Delaware |
|
| March 12, 2015 |
MLSS / Milestone Scientific Inc. / Gintel Robert M Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Milestone Scientific Inc. (Name of Issuer) Common Stock, $0.001 Par Value per Share (Title of Class of Securities) 59935P100 (CUSIP Number) March 9, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 20, 2015 |
8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2015 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 0-26284 13-3545623 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 9, 2015 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 1, 2015 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILES |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
|
| June 6, 2014 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2014 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 001-14053 13-3545623 (State or other jurisdiction of incorporation) (Commissi |
|
| May 27, 2014 |
EX-99.1 2 d733962dex991.htm EX-99.1 Exhibit 99.1 Investor Relations: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: [email protected] Tel: 212-671-1020 Milestone Scientific Appoints Gian Domenico Trombetta as President & CEO of its Dental Division Joins Milestone Scientific Board of Directors LIVINGSTON, NJ, May 27, 2014 — Milestone Scientific Inc. (OTCQB: MLSS), a leadin |
|
| May 27, 2014 |
EX-99.B Exhibit B REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of May 14, 2014, by and among Milestone Scientific Inc., a Delaware corporation (“Company”), and BP4 S.r.l., an Italian corporation (the “Purchaser”). WHEREAS, this Agreement is made pursuant to an Investment Agreement, dated as of April 15, 2014 (the “Investment Agreement”). Capitalize |
|
| May 27, 2014 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2014 MILESTONE SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 0-26284 13-3545623 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 27, 2014 |
MLSS / Milestone Scientific Inc. / Bp4 S.r.l. - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* MILESTONE SCIENTIFIC INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 59935P100 (CUSIP Number) BP4 S.r.l. c/o Innovest S.p |
|
| May 15, 2014 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| May 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14053 MILESTONE |
